Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07542041 · ClinicalTrials.gov registry record · NA
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
A NA study, sponsored by ARTIDIS.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT07542041: Recruiting NA study, sponsored by ARTIDIS.
NCT07542041 is a NA study that is actively recruiting participants, run by ARTIDIS. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07542041, a NA study, is actively recruiting participants, sponsored by ARTIDIS.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study aims to answer are: * Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer? * How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment? This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance. Participants will: * Undergo a standard-of-care pancreatic biopsy or surgical procedure * Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device * Continue to receive standard treatment and care, which is not influenced by the study * Have clinical data, imaging results, and treatment outcomes collected * Be followed every 3 months for up to 2 years The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
Interventions
- DEVICE ARTIDIS ART-1 Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-04 |
| Est. Completion | 2030-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07542041
The ClinicalTrials.gov registry entry for NCT07542041 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARTIDIS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARTIDIS ART-1 Device is the first listed.
NCT07542041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07542041 about?
NCT07542041 is a clinical study titled "Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens". The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study ai...
What is the current status of trial NCT07542041?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2026-04. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07542041?
The interventions under investigation include: ARTIDIS ART-1 Device (DEVICE).
Who is sponsoring clinical trial NCT07542041?
This trial is sponsored by ARTIDIS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.